Syncona Share News (SYNC)

Syncona Information

Buy SYNC Shares
Add SYNC to Watchlist
Add SYNC to Alert

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 110.00

Bid: 110.00

Ask: 110.20

Change: 1.60 (1.48%)

Spread: 0.20 (0.182%)

Open: 107.40

High: 110.20

Low: 107.40

Prev. Close: 108.40

Last checked at -

Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

IN BRIEF: Syncona notes investee company's quarterly loss

Tue, 14th Nov 2023 11:29

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Current stock price: 127.32 pence, down 0.7%

12-month change: down 33%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

More News

3 Aug 2020 22:16

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

20 Jul 2020 08:44

Syncona Investee Freeline Therapeutics Files For Possible US Listing

20 Jul 2020 07:22

Syncona's Freeline files IPO registration document

(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).

13 Jul 2020 18:36

Syncona's Investee Freeline Publishes Further Data For FLT180a

30 Jun 2020 10:33

Syncona Investee Freeline Raises USD120 Million And Mulls US Listing

30 Jun 2020 08:26

Syncona revalues holding in Freeline after expanded series C

(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.

18 Jun 2020 16:40

DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares

15 Jun 2020 09:19

Former Bayer Healthcare Chief Medical Officer Malik Joins Syncona

11 Jun 2020 09:26

Syncona Annual Assets Take Hit From Autolus Value But Likes Portfolio

11 Jun 2020 08:32

Syncona asset values fall after Autolus shares plunge

(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.

4 Jun 2020 18:21

UK Earnings, Trading Statements Calendar - Next 7 Days

29 May 2020 09:07

Syncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial

29 May 2020 08:12

Syncona portfolio firm Achilles doses first patient in T cell therapy trial

(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.

23 Apr 2020 11:01

Syncona Makes USD51 Million Investment Into SwanBio Therapeutics

23 Apr 2020 08:54

Syncona announces expanded commitment to SwanBio

(Sharecast News) - Syncona announced a new $51m (?41.39m) commitment in an expanded $77m series A round of financing by SwanBio Therapeutics on Thursday.

Latest Share Chat

Syncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Syncona notes investee company's quarterly loss

Login to your account

Quickpicks are a member only feature

Login to your account